Meeting
2024 ASCO Gastrointestinal Cancers Symposium
FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.
Authors
Michael Bitzer
Department for Internal Medicine I, Center for Personalized Medicine; Cluster of Excellence iFIT (EXC2180), Eberhard-Karls University, Tübingen, Germany
Michael Bitzer , Christopher Hackenbruch , Jens Bauer , Jonas S. Heitmann , Yacine Maringer , Annika Nelde , Helmut R. Salih , Juliane S. Walz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05937295
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr TPS580)
DOI
10.1200/JCO.2024.42.3_suppl.TPS580
Abstract #
TPS580
Poster Bd #
P9
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase I trial of perioperative chemotherapy plus immunotherapy in localized esophageal and gastroesophageal adenocarcinoma.
First Author: Mariela A. Blum Murphy
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Glycoprotein D, a checkpoint inhibitor of early T-cell activation, to improve immunogenicity and efficacy of an HPV-16 vaccine in preclinical studies.
First Author: Hildegund Ertl
Poster
2024 ASCO Annual Meeting
A first-in-human phase 1 trial of T cell membrane-anchored tumor targeted IL12 (ATTIL12) -T cell therapy in advanced/metastatic soft tissue and bone sarcoma.
First Author: J. Andrew Livingston
Poster
2024 ASCO Annual Meeting
SB221: A proof-of-concept study to assess the combination of SON-1010 (IL12-FHAB) and atezolizumab in patients with platinum-resistant ovarian cancer.
First Author: Sant P. Chawla